TandemAI is focused on lowering the barrier to entry to the most advanced tools in drug discovery. We designed our fully integrated pre-clinical drug discovery platform to empower researchers to discover therapeutic candidates faster and more efficiently by democratizing access to the most innovative tools in drug discovery. We hope to dramatically improve the success rate of pre-clinical therapeutic candidates and, ultimately, help improve the lives of people waiting for new treatment options.
TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery
TandemAI Announces Appointment of Alessandro Monge, Ph.D., as Chief Business Officer
TandemAI Announces Appointment of Steve Swann, Ph.D., as Chief Scientific Officer